{"id":"https://openalex.org/W4310099669","doi":"https://doi.org/10.1182/blood-2022-164905","title":"A Phase II Trial of the Combination of Obinutuzumab, Venetoclax, and Ibrutinib in Patients with Previously Untreated Follicular Lymphoma","display_name":"A Phase II Trial of the Combination of Obinutuzumab, Venetoclax, and Ibrutinib in Patients with Previously Untreated Follicular Lymphoma","publication_year":2022,"publication_date":"2022-11-15","ids":{"openalex":"https://openalex.org/W4310099669","doi":"https://doi.org/10.1182/blood-2022-164905"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2022-164905","doi":"https://doi.org/10.1182/blood-2022-164905","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2022-164905","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5036721372","display_name":"Tamer Adel Othman","orcid":"https://orcid.org/0000-0001-6376-4495","observed_orcids":["https://orcid.org/0000-0001-6376-4495"]},"institutions":[{"id":"https://openalex.org/I4390039352","display_name":"UC Davis Comprehensive Cancer Center","ror":"https://ror.org/02kcc1z29","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210160856","https://openalex.org/I4390039352"]},{"id":"https://openalex.org/I84218800","display_name":"University of California, Davis","ror":"https://ror.org/05rrcem69","country_code":"US","type":"education","lineage":["https://openalex.org/I84218800"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tamer Othman","raw_affiliation_strings":["1University of California Davis Comprehensive Cancer Center, Sacramento, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1University of California Davis Comprehensive Cancer Center, Sacramento, CA","institution_ids":["https://openalex.org/I4390039352","https://openalex.org/I84218800"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047442341","display_name":"Aaron Seth Rosenberg","orcid":"https://orcid.org/0000-0003-0714-734X","observed_orcids":["https://orcid.org/0000-0003-0714-734X"]},"institutions":[{"id":"https://openalex.org/I4210160856","display_name":"UC Davis Health","ror":"https://ror.org/05q8kyc69","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210160856"]},{"id":"https://openalex.org/I84218800","display_name":"University of California, Davis","ror":"https://ror.org/05rrcem69","country_code":"US","type":"education","lineage":["https://openalex.org/I84218800"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Aaron S Rosenberg","raw_affiliation_strings":["2Cancer Center Data Informatics Integration Initiative (CDI3), University of California Davis Health System Department of Research Informatics, Sacramento, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Cancer Center Data Informatics Integration Initiative (CDI3), University of California Davis Health System Department of Research Informatics, Sacramento, CA","institution_ids":["https://openalex.org/I4210160856","https://openalex.org/I84218800"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5107833759","display_name":"John M. Timmerman","orcid":"https://orcid.org/0000-0003-4104-8943","observed_orcids":["https://orcid.org/0000-0003-4104-8943"]},"institutions":[{"id":"https://openalex.org/I2801272649","display_name":"Ronald Reagan UCLA Medical Center","ror":"https://ror.org/04k3jt835","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799798094","https://openalex.org/I2801272649"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John Timmerman","raw_affiliation_strings":["3UCLA Medical Center, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3UCLA Medical Center, Los Angeles, CA","institution_ids":["https://openalex.org/I2801272649"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047231615","display_name":"Benjamin Michael Heyman","orcid":"https://orcid.org/0000-0001-6707-0861","observed_orcids":["https://orcid.org/0000-0001-6707-0861"]},"institutions":[{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]},{"id":"https://openalex.org/I4390039236","display_name":"Moores Cancer Center","ror":"https://ror.org/01qkmtm61","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800935791","https://openalex.org/I36258959","https://openalex.org/I4390039236"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Benjamin Heyman","raw_affiliation_strings":["4Moores Cancer Center, University of California, San Diego, La Jolla, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Moores Cancer Center, University of California, San Diego, La Jolla, CA","institution_ids":["https://openalex.org/I36258959","https://openalex.org/I4390039236"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077589098","display_name":"Haifaa Abdulhaq","orcid":"https://orcid.org/0000-0002-3549-0981","observed_orcids":["https://orcid.org/0000-0002-3549-0981"]},"institutions":[{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Haifaa Abdulhaq","raw_affiliation_strings":["5Hematology/Oncology, University of California San Francisco-Fresno, Fresno, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Hematology/Oncology, University of California San Francisco-Fresno, Fresno, CA","institution_ids":["https://openalex.org/I180670191"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5045079164","display_name":"Joseph M. Tuscano","orcid":"https://orcid.org/0000-0002-0522-1406","observed_orcids":["https://orcid.org/0000-0002-0522-1406"]},"institutions":[{"id":"https://openalex.org/I4390039352","display_name":"UC Davis Comprehensive Cancer Center","ror":"https://ror.org/02kcc1z29","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210160856","https://openalex.org/I4390039352"]},{"id":"https://openalex.org/I84218800","display_name":"University of California, Davis","ror":"https://ror.org/05rrcem69","country_code":"US","type":"education","lineage":["https://openalex.org/I84218800"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joseph M Tuscano","raw_affiliation_strings":["1University of California Davis Comprehensive Cancer Center, Sacramento, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1University of California Davis Comprehensive Cancer Center, Sacramento, CA","institution_ids":["https://openalex.org/I4390039352","https://openalex.org/I84218800"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":7,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":2500,"currency":"USD","value_usd":2500},"apc_paid":null,"fwci":0.1693,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.48431076,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":93},"biblio":{"volume":"140","issue":"Supplement 1","first_page":"11954","last_page":"11955"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.7588000297546387,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.7588000297546387,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.23880000412464142,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11811","display_name":"Cutaneous lymphoproliferative disorders research","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/follicular-lymphoma","display_name":"follicular lymphoma","score":0.9769999980926514},{"id":"https://openalex.org/keywords/obinutuzumab","display_name":"obinutuzumab","score":0.9750000238418579},{"id":"https://openalex.org/keywords/venetoclax","display_name":"venetoclax","score":1.0},{"id":"https://openalex.org/keywords/ibrutinib","display_name":"ibrutinib","score":1.0},{"id":"https://openalex.org/keywords/bcl-2","display_name":"Bcl-2","score":0.628000020980835},{"id":"https://openalex.org/keywords/b-cell-receptor-signaling","display_name":"B cell receptor signaling","score":0.7960000038146973},{"id":"https://openalex.org/keywords/bcl-2-family-proteins","display_name":"Bcl-2 family proteins","score":0.675000011920929},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.5680000185966492},{"id":"https://openalex.org/keywords/previously-untreated-lymphoma","display_name":"previously untreated lymphoma","score":0.8389999866485596},{"id":"https://openalex.org/keywords/complete-response-rate","display_name":"complete response rate","score":0.8240000009536743},{"id":"https://openalex.org/keywords/overall-response-rate","display_name":"overall response rate","score":0.753000020980835},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.7639999985694885},{"id":"https://openalex.org/keywords/treatment-safety","display_name":"treatment safety","score":0.40400001406669617},{"id":"https://openalex.org/keywords/bcl-2-inhibitor-resistance","display_name":"BCL-2 inhibitor resistance","score":0.5199999809265137}],"concepts":[{"id":"https://openalex.org/C2779675984","wikidata":"https://www.wikidata.org/wiki/Q23671272","display_name":"Venetoclax","level":4,"score":0.9590625762939453},{"id":"https://openalex.org/C2777607594","wikidata":"https://www.wikidata.org/wiki/Q389496","display_name":"Obinutuzumab","level":4,"score":0.8479560613632202},{"id":"https://openalex.org/C2779878957","wikidata":"https://www.wikidata.org/wiki/Q5984881","display_name":"Ibrutinib","level":4,"score":0.8455689549446106},{"id":"https://openalex.org/C2777058707","wikidata":"https://www.wikidata.org/wiki/Q123251","display_name":"Follicular lymphoma","level":3,"score":0.7269989252090454},{"id":"https://openalex.org/C2777525834","wikidata":"https://www.wikidata.org/wiki/Q268713","display_name":"Mantle cell lymphoma","level":3,"score":0.627101480960846},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5410470366477966},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4647507071495056},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.45618075132369995},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.4551737904548645},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.41466042399406433},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3287220001220703},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.2843553125858307},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.2755316197872162},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.25537070631980896}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2022-164905","doi":"https://doi.org/10.1182/blood-2022-164905","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2022-164905","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4417012966","https://openalex.org/W2951735615","https://openalex.org/W4417009167","https://openalex.org/W3214226433","https://openalex.org/W3096316159","https://openalex.org/W4410300601","https://openalex.org/W6929483563","https://openalex.org/W2600359049","https://openalex.org/W4405046028","https://openalex.org/W4411248969"],"abstract_inverted_index":{"Background:":[0],"Follicular":[1],"lymphoma":[2],"(FL)":[3],"is":[4,38,567],"typically":[5],"associated":[6],"with":[7,64,80,140,153,486],"the":[8,18,25,59,81,85,112,279,547,556],"BCL-2":[9,45],"chromosome":[10],"translocation":[11],"t(14:18),":[12],"which":[13],"leads":[14],"to":[15,49,52,95,311,464,479,529,584],"overexpression":[16],"of":[17,34,87,114,145,175,183,195,207,219,248,289,302,316,329,413,470,489,552,558],"intracellular":[19],"anti-apoptotic":[20],"protein":[21],"BCL-2.":[22],"In":[23],"addition,":[24],"B-cell":[26,42],"receptor":[27],"(BCR)":[28],"promotes":[29],"development,":[30],"proliferation,":[31],"and":[32,37,90,105,117,126,170,205,225,251,292,324,341,351,378,392,450,483,501,508,550,561,566,579],"survival":[33],"normal":[35],"B-cells,":[36],"frequently":[39],"manipulated":[40],"in":[41,98,103,121,346,462,498],"malignancies.":[43],"The":[44,332,349,402,410,420,538],"family":[46],"are":[47,56,344],"hypothesized":[48,110],"confer":[50],"resistance":[51],"venetoclax.":[53],"These":[54],"proteins":[55],"up-regulated":[57],"by":[58,269,278],"tumor":[60],"microenvironment":[61],"but":[62],"down-regulated":[63],"ibrutinib.":[65],"Xenograft":[66],"models":[67],"have":[68],"shown":[69,94],"that":[70,111],"venetoclax":[71,463,500],"+":[72],"obinutuzumab":[73],"demonstrates":[74],"significantly":[75],"increased":[76],"anti-tumor":[77],"activity":[78],"compared":[79],"agents":[82],"individually.":[83],"Finally,":[84],"combination":[86,113,557],"obinutuzumab,":[88,115,559],"venetoclax,":[89,116,560],"ibrutinib":[91,118,502,562],"has":[92],"been":[93],"be":[96],"safe":[97],"prior":[99],"phase":[100,136],"I":[101],"trials":[102],"CLL":[104],"mantle":[106],"cell":[107],"lymphoma.":[108],"We":[109,133],"would":[119],"result":[120],"synergism":[122],"enhancing":[123],"their":[124],"efficacy,":[125],"report":[127],"our":[128],"preliminary":[129],"results":[130],"here.":[131],"Methods:":[132],"conducted":[134],"a":[135,141,233,306,382,393,459,487,568],"II,":[137],"open-label":[138],"trial":[139],"planned":[142],"sample":[143,548],"size":[144,549],"40":[146],"patients":[147,149,321,357,524,541],"involving":[148],"\u226518":[150],"years":[151],"old":[152],"previously":[154],"untreated":[155,573],"FL.":[156,574],"Obinutuzumab":[157],"1000":[158],"mg":[159,224,241,466],"IV":[160],"was":[161,211,237,263,298,335,405,416,509],"given":[162,238],"on":[163,189,213,242,272,467,543],"days":[164,468,474,518],"1,":[165,177],"8":[166,320],"(\u00b1":[167,172,180,192,216,245],"2":[168,173,185,217,246,376,436,440],"days),":[169],"15":[171],"days)":[174,182,194,218,247],"cycle":[176,196,220,230,249,255,472],"day":[178,190,214,243],"1":[179,191,221,244,250,367,379,429,448],"7":[181,193],"cycles":[184,208,391,414],"through":[186,229,254],"6,":[187],"then":[188],"8,":[197],"10,":[198],"12,":[199],"14,":[200],"16,":[201],"18,":[202],"20,":[203],"22,":[204],"24":[206,231],"7-24.":[209],"Venetoclax":[210],"started":[212],"4":[215,453],"at":[222,239],"400":[223,465],"continued":[226,252],"once":[227],"daily":[228,253],"without":[232],"ramp":[234],"up.":[235],"Ibrutinib":[236],"560":[240],"24.":[256],"Cycles":[257],"were":[258,322,353,423,533,554,577],"28":[259],"days.":[260],"Primary":[261],"endpoint":[262],"complete":[264,309],"response":[265,285,290,326,362,373,384,387,397],"rate":[266,286],"(CRR),":[267],"determined":[268],"PET/CT":[270],"based":[271],"Lugano":[273],"2014":[274],"criteria,":[275],"as":[276,300,328],"assessed":[277],"investigator.":[280],"Secondary":[281],"endpoints":[282],"included":[283],"overall":[284],"(ORR),":[287],"duration":[288,551],"(DoR),":[291],"treatment-emergent":[293],"adverse":[294],"events":[295],"(TEAEs).":[296],"DoR":[297,404],"defined":[299],"time":[301],"first":[303,361,372,386],"response,":[304,310],"either":[305],"partial":[307,383],"or":[308,314],"progression,":[312],"death,":[313],"date":[315],"last":[317],"follow-up.":[318],"Results:":[319],"enrolled":[323],"underwent":[325],"evaluation":[327],"July":[330],"20,2022.":[331],"median":[333,403,411],"follow-up":[334,553],"12.2":[336],"months":[337],"(IQR,":[338],"11.3;14.3).":[339],"Patient":[340],"disease":[342],"characteristics":[343],"summarized":[345],"Table":[347],"1.":[348],"CRR":[350],"ORR":[352],"each":[354,471],"100%.":[355],"6/8":[356],"achieved":[358,369,381],"CR":[359,370,394],"upon":[360,371,385,395],"assessment":[363,374,388,398],"after":[364,375,389,399,475,519],"3":[365,390,426,433,444,481],"cycles,":[366,377],"patient":[368,380,457,485,530],"second":[396],"6":[400],"cycles.":[401],"not":[406],"reached":[407],"(Figure":[408],"1).":[409],"number":[412],"completed":[415],"9":[417],"(range,":[418],"6-15).":[419],"TEAEs":[421],"observed":[422],"fatigue":[424],"[grade":[425,432,439,443,447,452],"(n=3),":[427],"grade":[428,435,480,505],"(n=2)],":[430],"lymphopenia":[431],"(n=2),":[434],"(n=1)],":[437,441,445,449],"diarrhea":[438],"neutropenia":[442],"rash":[446],"thrombocytopenia":[451,507],"(n=1)]":[454],".":[455],"One":[456],"required":[458,494],"dose":[460,496],"reduction":[461],"1-10":[469],"222":[473],"starting":[476,520],"treatment":[477],"due":[478,528],"fatigue,":[482],"one":[484],"history":[488],"immune":[490],"thrombocytopenic":[491],"purpura":[492],"(ITP)":[493],"multiple":[495],"reductions":[497],"both":[499],"for":[503,514,572],"recurring":[504],"\u22653":[506],"eventually":[510],"taken":[511],"off":[512],"study":[513],"this":[515],"reason":[516],"241":[517],"treatment.":[521,544],"Two":[522],"other":[523,535,539],"discontinued":[525],"therapy":[526],"early":[527],"choice.":[531],"There":[532],"no":[534,580],"treatment-related":[536],"discontinuations.":[537],"5":[540],"remain":[542],"Conclusion:":[545],"Although":[546],"limited,":[555],"demonstrated":[563],"remarkable":[564],"efficacy":[565],"promising":[569],"non-chemotherapeutic":[570],"alternative":[571],"Non-hematologic":[575],"toxicities":[576],"manageable,":[578],"hematologic":[581],"toxicity":[582],"led":[583],"clinical":[585],"complications.":[586],"Figure":[587],"1View":[588,591],"largeDownload":[589,592],"PPTFigure":[590],"PPT":[593],"Close":[594],"modal":[595]},"counts_by_year":[{"year":2023,"cited_by_count":1}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2022-11-30T00:00:00"}